Compass Therapeutics (NASDAQ:CMPX) Coverage Initiated at D. Boral Capital

D. Boral Capital assumed coverage on shares of Compass Therapeutics (NASDAQ:CMPX) in a note issued to investors on Monday,Benzinga reports. The brokerage set a “buy” rating and a $32.00 price target on the stock.

A number of other analysts have also recently commented on CMPX. HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of Compass Therapeutics in a research report on Monday, November 11th. Leerink Partners lowered Compass Therapeutics from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $5.00 to $4.00 in a research report on Friday, November 15th. LADENBURG THALM/SH SH raised Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 target price for the company in a research note on Monday, September 16th. Finally, Leerink Partnrs lowered shares of Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 15th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $11.80.

Compass Therapeutics Trading Up 0.7 %

Compass Therapeutics stock opened at $1.38 on Monday. The firm has a market capitalization of $189.87 million, a P/E ratio of -3.73 and a beta of 0.89. The business has a 50-day moving average of $1.65 and a 200-day moving average of $1.41. Compass Therapeutics has a 1 year low of $0.77 and a 1 year high of $2.34.

Compass Therapeutics (NASDAQ:CMPX) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.03. Research analysts anticipate that Compass Therapeutics will post -0.35 EPS for the current fiscal year.

Institutional Investors Weigh In On Compass Therapeutics

Several institutional investors have recently bought and sold shares of the company. Ground Swell Capital LLC bought a new position in shares of Compass Therapeutics during the 2nd quarter worth approximately $124,000. Barclays PLC grew its position in Compass Therapeutics by 195.4% in the third quarter. Barclays PLC now owns 170,245 shares of the company’s stock valued at $314,000 after purchasing an additional 112,614 shares in the last quarter. Renaissance Technologies LLC increased its stake in Compass Therapeutics by 99.7% in the 2nd quarter. Renaissance Technologies LLC now owns 140,600 shares of the company’s stock valued at $141,000 after buying an additional 70,200 shares during the last quarter. Panagora Asset Management Inc. bought a new stake in Compass Therapeutics during the 2nd quarter worth about $68,000. Finally, The Manufacturers Life Insurance Company acquired a new position in shares of Compass Therapeutics during the 3rd quarter worth about $79,000. Institutional investors own 68.43% of the company’s stock.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.